Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

5/7/25 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FOLD alert in real time by email

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. P.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations

[email protected]

(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Affairs and Communications

[email protected]

(609) 662-5079

FOLD–G

Get the next $FOLD alert in real time by email

Date	Price Target	Rating	Analyst
12/13/2024	$17.00 → $12.00	Overweight → Equal-Weight	Morgan Stanley
9/6/2024	$18.00	Buy	Jefferies
5/30/2024	$18.00	Overweight	Wells Fargo
5/14/2024	$13.00	Neutral → Buy	Guggenheim
12/19/2023	$15.00 → $20.00	Equal-Weight → Overweight	Morgan Stanley
9/9/2022	$14.00	Equal-Weight	Morgan Stanley
4/13/2022	$11.00	Neutral	Goldman
2/24/2022	$16.00 → $14.00	Outperform	SVB Leerink

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

Chat with this insight

Recent Analyst Ratings for
$FOLD

$FOLD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Mcglynn Margaret G was granted 20,414 shares, increasing direct ownership by 29% to 91,550 units (SEC Form 4)

Director Raab Michael was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

Director Sblendorio Glenn was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

$FOLD
Press Releases

Fastest customizable press release news feed in the world

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

$FOLD
SEC Filings

SEC Form S-8 filed by Amicus Therapeutics Inc.

Amicus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

Chat with this insight

Recent Analyst Ratings for $FOLD

$FOLD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Mcglynn Margaret G was granted 20,414 shares, increasing direct ownership by 29% to 91,550 units (SEC Form 4)

Director Raab Michael was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

Director Sblendorio Glenn was granted 20,414 shares, increasing direct ownership by 21% to 115,857 units (SEC Form 4)

$FOLD Press Releases

Fastest customizable press release news feed in the world

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

$FOLD SEC Filings

SEC Form S-8 filed by Amicus Therapeutics Inc.

Amicus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

Recent Analyst Ratings for
$FOLD

$FOLD
Insider Trading

$FOLD
Press Releases

$FOLD
SEC Filings